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INTRODUCTION
Diagnostic laparoscopy as a tool to identify candidates 
for primary cytoreductive surgery among patients with 
advanced stage ovarian cancer has been suggested, but 
remains controversial [1]. It has been reported that diagnostic 
laparoscopy contributed to selecting patients for primary 
surgery giving optimal cytoreduction in 61-96% of cases [2-4]. 
The use of laparoscopy in the management of cancer patients 
has brought many advantages such as shorter recovery time, 
improved performance, potential to initiate neoadjuvant 
therapy earlier, and decreased risk of developing adhesions. 
However, there are also disadvantages of tumor recurrences 
and metastases at the trocar insertion sites [5]. In 1978, port-
site metastasis was defined subsequent to laparoscopy for the 
first time in an ovarian cancer patient by Dobronte et al. [6] 
The incidence of port-site metastasis for gynecological cancers 
is defined between 1.1-16% per procedure [7-10]. Herein, 
we present two cases with port-site metastasis diagnosed 
during neoadjuvant chemotherapy prior to primary surgery 
regardless of chemotherapy.
CASE REPORT
1. Case 1
A 63 year-old menopausal woman referred with complaints 
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possible poor prognosis of these patients, especially those who have ascites, should make us careful in performing diagnostic 
laparoscopy with preventive measures for port-site metastasis and to start the chemotherapy immediately.
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of abdominal distention, vaginal bleeding, and loss of appe-
tite. Ultrasonography revealed bilaterally enlarged ovaries 
(right 13x8x8 cm, left 12x10x9 cm) with multiple cystic and 
solid lesions and intra-abdominal ascites. The CA-125 level 
was 2,340 U/mL and the other tumor markers were within 
the normal range. Subsequently, a diagnostic laparoscopy 
was performed to evaluate operability of the patient as she 
had large bulky masses on ultrasonography. The laparoscopy 
revealed massive ascites, enlarged ovaries, and multiple 
diaphragmatic and peritoneal implants, along with an omen-
tal cake, and multiple biopsies were taken from the ovaries, 
omental cake, and peritoneal implants. There were 3 ports 
at the umbilicus (10 mm) and bilateral inguinal areas (both 5 
mm), and the harvesting port was the left inguinal one. The 
pathological assessment revealed serous papillary ova  rian 
cancer and multiple metastases to the peritoneal and serosal 
surfaces. Subsequently, neoadjuvant chemotherapy com-
prising cisplatinum (75 mg/m
2) and paclitaxel (175 mg/m
2) for 
4 courses was given. CA-125 levels were measured as 1,999 U/
mL, 944 U/mL, 368 U/mL and 160 U/mL at the chemotherapy 
courses, respectively. A subcutaneous, 2x1 cm diameter 
nodule was noticed on the 3rd neoadjuvant chemo  therapy 
course, 47 days after the laparoscopic procedure, regardless of 
treatment. Subsequent to the 4th neoadjuvant chemotherapy 
course, primary debulking surgery including excision of port-
site metastasis was performed, and the residual tumor size 
was <1 cm. The pathological assessment revealed poorly 
differented serous papillary ovarian cancer with invasion of 
bilateral ovarian surfaces, parametrium, serosal surfaces of 
tubes, uterus and appendix, as well with multiple invasions of 
the omentum. Furthermore, metastases of the periaortic (1/4) 
and right pelvic (1/6) lymph nodes were detected. Metastasis 
to the port-site was also diagnosed with pathological 
assessment of the 21x14 mm skin and subcutaneous tissue 
specimen which was excised from the right inguinal area 5 
mm port-site. The patient had 6 courses of adjuvant chemo-
therapy consisting of cisplatinum (75 mg/m
2) and paclitaxel 
(175 mg/m
2) subsequent to the surgery. After the last course 
CA-125 levels were 32 U/mL. Thereafter patient was taken to 
the follow-up program and she had no signs of recurrence 12 
months after the last adju  vant chemotherapy course.
2. Case 2
A 66 year-old woman was referred with a complaint of 
abdominal distention. Her initial gynecological and trans-
vaginal ultrasonographic examination revealed bilateral en-
larged ovaries (right 7x6x5 cm, left 6x6x9 cm) with multiple 
cystic and solid lesions and intra-abdominal ascites. The CA-
125 level was 954 U/mL and the other tumor markers were 
normal. The cytological analysis of the ascites revealed an 
adenocarcinoma. Therefore, a diagnostic laparoscopy was 
performed to evaluate operability of the patient as she had 
a frozen pelvis on the bimanual gynecological examination 
and massive ascites, bilaterally enlarged ovaries, multiple 
implants of the diaphragm, peritoneal and serosal surfaces 
were determined, and multiple biopsies were taken from the 
ovaries and peritoneal surfaces. The three ports used during 
the procedure were 10 mm at the umbilicus and 5 mm at 
the bilateral inguinal areas. The harvesting port was the left 
inguinal one. The pathological assessment revealed a serous 
papillary ovarian cancer and multiple metastases to the 
peritoneal and serosal surfaces. Subsequently, neoadjuvant 
chemotherapy comprising of cisplatinum (75 mg/m
2) and 
paclitaxel (175 mg/m
2) was given for 4 courses with 21 day 
intervals. The level of CA-125 was 160 U/mL after the last 
chemotherapy course. A paraumbilical, 3x2 cm diameter 
subcutaneous nodule was noticed at the 10 mm port site 
after the second neoadjuvant chemotherapy course, 28 days 
after the laparoscopic procedure. Neoadjuvant chemotherapy 
was continued and the patient underwent primary debulking 
surgery. Port-site metastasis was also excised and the residual 
tumor size was <1 cm. The pathological assessment revealed 
serous papillary adenocarcinoma of the ovary with invasion 
of bilateral ovarian surfaces, parametrium, serosal surfaces 
of tubes, uterus and appendix as well multiple invasions 
of the omentum. Furthermore, metastases to pelvic (2/4) 
lymph nodes were reported. Metastasis to the port-site was 
also diagnosed by pathological assessment (Fig. 1). The 
patient had 6 courses of adjuvant chemotherapy consisting 
of cisplatinum (75 mg/m
2) and paclitaxel (175 mg/m
2) 
subsequent to the surgery. After the last course CA-125 levels 
Fig. 1. Metastatic tumor nodule with evident papillary pattern in the 
subcutaneous adipose tissue (H&E, x40).Port site metastasis during neoadjuvant chemotherapy
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were 35 U/mL. Thereafter the patient was taken to the follow-
up program and she had no signs of recurrence 6 months 
after the last adjuvant chemotherapy course.
DISCUSSION
Diagnostic laparoscopy has become a preferred technique 
to evaluate operability of ovarian cancers. But one of the 
major concerns of laparoscopy in ovarian cancers is the 
development of port-site metastasis. Port site metastasis after 
diagnostic laparoscopy during neoadjuvant chemotherapy is 
an extremely rare situation [11]. In the vast majority (71%) of 
the cases the metastasis was isolated to and diagnosed at the 
“manipulation port” which is described as the port whereby 
instruments for biopsies inserted or extraction of tumor 
biopsies were done [12]. The median time to development of 
port-site metastasis was calculated as 17 days (range, 4 to 730 
days) [12].
The potential risk factors for port-site metastasis are 
insufflation with carbon dioxide (tissue acidosis), high efflux of 
gas from the abdominal cavity through the space around the 
trocars (chimney effect), influence of local immune system, 
surgical technique, and the potential for contamination of 
the trocar site with viable tumor cells and presence of ascites 
[12,13]. According to Wang et al. [14] presence of ascites is 
significantly associated with the early occurrence of port-
site metastases. There are some recommended measures 
to prevent port-site metastasis which include using wound 
protectors, minimal tumor manipulation, avoiding CO2 leaks 
and sudden desufflations, performing gasless laparoscopy, 
irrigation of ports with heparin or povidone-iodine solution 
before removal, excision of trocar sites and deliberate closure 
of all abdominal layers including the peritoneum, and early 
chemotherapy [9]. However, there is not enough evidence 
of effective prevention of port-site metastasis [9]. In Table 1 
the two patients are summarized with risk factors for port-site 
metastasis.
Although there are reports about poor outcome with port-
site metastasis during neoadjuvant chemotherapy in patients 
who have ascites, it has also reported that port-site metastasis 
do not affect the prognosis [8,12,13]. According to the study 
of van Dam et al. [8], port-site metastasis during neoadjuvant 
chemotherapy does not have a significant impact on the 
outcome. However, according to the study of Huang et 
al. [13], those patients who had port-site-metastasis that 
develop during chemotherapy have poor prognosis, and all 
died because of the cancer. The management of port-site 
metastases is primary excision of the tumor during debulking 
surgery. Despite the presence of ascites and occurrence 
during neoadjuvant chemotherapy, the treatment seems to 
be successful in our patients for the short duration of follow-
up (Table 1). 
The role of laparoscopy in ovarian malignancies is still a 
matter of debate. Although it has many benefits, there is a risk 
of port-site metastasis especially in advanced ovarian cancer 
patients who have ascites. Therefore, we should try to perform 
the preventive measures in practice as much as possible, 
and because of its possible poor prognosis we should start 
neoadjuvant chemotherapy course immediately. Anyhow, if 
port-site metastasis occurs the management should be local 
excision during debulking surgery.
Table 1. Summary of the two advanced stage ovarian cancer patients with early port-site metastasis 
Case 1 Case 2
Age 63 66
Stage IIIC IIIC
Histology Serous papillary Serous papillary
Residual tumor <1 cm <1 cm
Chemotherapy Cisplatinum
Paclitaxel
Cisplatinum 
Paclitaxel 
Time of occurrence of port-site metastasis 47 days 28 days
Treatment Surgical excision Surgical excision
Risk factors Advanced malignancy
Ascites
Insufflation with CO2
Advanced malignancy 
Ascites
Insufflation with CO2
Used prevention effort Minimal tumor manipulation
Early chemotherapy
Minimal tumor manipulation
Early chemotherapy
Clinical outcome Disease free 12 mo Disease free 6 moBatuhan Özmen, et al.
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